阿托伐他汀联合培哚普利对高血压合并冠心病患者血小板活化功能、内皮功能与心功能的影响
|
摘要
目的研究阿托伐他汀联合培哚普利对高血压合并冠心病患者血小板活化功能、内皮功能及心功能的影响。方法采取回顾性分析法对2015年12月—2017年12月期间驻马店市遂平仁安医院接收的高血压合并冠心病患者126例展开研究,随机分为对照组和观察组,均为63例,其中对照组单用培哚普利治疗,观察组则联用阿托伐他汀与培哚普利开展治疗。观察两组用药后血小板活化功能、血管内皮功能与心功能相关指标变化。结果治疗前两组左室舒张末期容积、左心室射血体积分数以及E峰/A峰值水平对比无统计学价值(P>0.05);治疗后,观察组左室舒张末期容积指标低于对照组(P<0.05);且观察组左心室射血体积分数以及E峰/A峰值水平高于对照组(P<0.05)。治疗前两组血管内皮功能指标内皮素-1、一氧化氮对比无统计学差异(P>0.05);经治疗后,观察组内皮素-1水平低于对照组(P<0.05),且一氧化氮指标水平高于对照组(P<0.05)。治疗前两组血小板活化功能指标括P-选择素、溶媒体膜蛋白糖水平比较无统计学差异(P>0.05);经治疗后,观察组P-选择素、溶媒体膜蛋白糖水平均低于对照组(P<0.05)。结论临床上治疗高血压合并冠心病患者采取阿托伐他汀联合培哚普利治疗法有助于稳定患者心功能指标,改善其血管内皮功能及血小板活化功能,有利于患者预后,该联合治疗方式值得推广。
Objective To study the effects of atorvastatin combined with perindopril on platelet activation, endothelial function and cardiac function in patients with hypertension complicated with coronary heart disease.Methods A retrospective analysis was performed on 126 patients with hypertension and coronary heart disease who were admitted to our hospital from December 2015 to December 2017. They were randomly divided into the control group and the observation group, all of which were 63 cases, of which the control group was used alone. Perindopril was given to the treatment group, and the observation group was treated with atorvastatin and perindopril. The changes of platelet activation, vascular endothelial function and cardiac function were observed after treatment.Results Left ventricular end-diastolic volume, left ventricular ejection volume fraction, and E-peak/A peak levels were not statistically significant(P>0.05). After treatment, the left ventricular end-diastolic volume index of the observation group was lower than that of the control group(P<0.05), and the left ventricular ejection volume fraction and E peak/A peak level in the observation group were higher than the control group(P<0.05). There was no significant difference in endothelin-1 and nitric oxide between the two groups before treatment(P>0.05). After treatment, the level of endothelin-1 in the observation group was lower than that in the control group(P<0.05). The level of nitric oxide was higher than that of the control group(P<0.05). There was no significant difference in the platelet activation function between the two groups, including P-selectin and soluble media membrane protein(P>0.05). After treatment, the P-selectin and soluble media membrane glycoprotein levels in the observation group were lower than that in the control group(P<0.05).Conclusion The combination of atorvastatin and perindopril in the treatment of patients with hypertension and coronary heart disease can help stabilize the heart function index, improve the vascular endothelial function and platelet activation, and benefit the prognosis of patients.
Objective To study the effects of atorvastatin combined with perindopril on platelet activation, endothelial function and cardiac function in patients with hypertension complicated with coronary heart disease.Methods A retrospective analysis was performed on 126 patients with hypertension and coronary heart disease who were admitted to our hospital from December 2015 to December 2017. They were randomly divided into the control group and the observation group, all of which were 63 cases, of which the control group was used alone. Perindopril was given to the treatment group, and the observation group was treated with atorvastatin and perindopril. The changes of platelet activation, vascular endothelial function and cardiac function were observed after treatment.Results Left ventricular end-diastolic volume, left ventricular ejection volume fraction, and E-peak/A peak levels were not statistically significant(P>0.05). After treatment, the left ventricular end-diastolic volume index of the observation group was lower than that of the control group(P<0.05), and the left ventricular ejection volume fraction and E peak/A peak level in the observation group were higher than the control group(P<0.05). There was no significant difference in endothelin-1 and nitric oxide between the two groups before treatment(P>0.05). After treatment, the level of endothelin-1 in the observation group was lower than that in the control group(P<0.05). The level of nitric oxide was higher than that of the control group(P<0.05). There was no significant difference in the platelet activation function between the two groups, including P-selectin and soluble media membrane protein(P>0.05). After treatment, the P-selectin and soluble media membrane glycoprotein levels in the observation group were lower than that in the control group(P<0.05).Conclusion The combination of atorvastatin and perindopril in the treatment of patients with hypertension and coronary heart disease can help stabilize the heart function index, improve the vascular endothelial function and platelet activation, and benefit the prognosis of patients.
引文
[1] Nargesi A,Esteghamati S,Heidari B,et al.Nonlinear relation between pulse pressure and coronary heart disease in patients with type 2 diabetes or hypertension[J].Eur J Neurol,2016,34(5):974-980.
[2] 马颖艳,韩雅玲.降脂治疗的新选择:PCSK9抑制剂[J].中华心血管病杂志,2019,47(2):164-167.
[3] 赵星星,贾永平,范春雨,等.阿托伐他汀联合依折麦布对冠心病患者脂代谢指标及炎症反应的影响[J].中国药物与临床,2019,19(4):590-592.
[4] 王一同,贾志梅.中国高血压防治指南的解读与分析[J].中国实用乡村医生杂志,2016,23(10):25-32.
[5] 李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[6] 田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响[J].海南医学院学报,2016,22(14):1489-1492.
[7] 吕园园,刘力,王志权.丹参川芎嗪注射液联合阿托伐他汀对冠心病并糖尿病患者血脂、血流变、内皮功能和心功能的影响[J].湖北中医药大学学报,2017,19(3):17-20.
[8] 李绍华,黄鸿辉,张永佳.强化阿托伐他汀治疗对急性心肌梗死患者急诊 PCI 术后 Lp-PLA2、IL-6 及心功能的影响[J].锦州医科大学学报,2018,39(2)64-66.
[9] Trine Moholdt,Carl J.Lavie,Javaid Nauman.Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease:Data from The Nord-Trndelag Health Study[J].Am J Med.2017 ,130(8):949-957.
[10] 贺卫国.培哚普利治疗冠心病患者心肌缺血的疗效[J].中国实用医刊,2011,38(20):62-64.
[11] 李翔宇,黄进,戴剑.培哚普利联合阿托伐他汀对高血压合并阵发性房颤患者炎症因子的干预作用[J].江苏医药,2016,42(24):2720-2722.
[12] 冷沁.氨氯地平并阿托伐他汀钙片改善高血压合并冠心病患者血脂和血压的效果[J].心血管康复医学杂志,2017,26(6):627-631.
[13] 王玉红,刘晖,冼志莲.阿托伐他汀联合阿司匹林对急性脑梗死患者血小板活化及炎性反应的影响[J].数理医药学杂志,2018,31(1):64-66.
[14] 陈伟,张亚西.硝苯地平控释片联合阿托伐他汀治疗高血压合并冠心病及对超敏C反应蛋白及血管内皮功能的影响[J].检验医学与临床,2015(1):40-42.
[15] 李广运.培哚普利联合瑞舒伐他汀治疗冠心病的疗效及对血管内皮功能与血小板活化功能的影响[J].中西医结合心脑血管病杂志,2018,16(1):70-73.
[16] 卓建明,林建武,钱文光,等.阿托伐他汀对急性脑梗死患者血浆炎症因子和血小板膜糖蛋白的影响[J].海峡药学,2010,22(3):101-102.
[2] 马颖艳,韩雅玲.降脂治疗的新选择:PCSK9抑制剂[J].中华心血管病杂志,2019,47(2):164-167.
[3] 赵星星,贾永平,范春雨,等.阿托伐他汀联合依折麦布对冠心病患者脂代谢指标及炎症反应的影响[J].中国药物与临床,2019,19(4):590-592.
[4] 王一同,贾志梅.中国高血压防治指南的解读与分析[J].中国实用乡村医生杂志,2016,23(10):25-32.
[5] 李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[6] 田磊.阿托伐他汀与曲美他嗪联合治疗对冠心病患者心功能、炎症因子和内皮功能的影响[J].海南医学院学报,2016,22(14):1489-1492.
[7] 吕园园,刘力,王志权.丹参川芎嗪注射液联合阿托伐他汀对冠心病并糖尿病患者血脂、血流变、内皮功能和心功能的影响[J].湖北中医药大学学报,2017,19(3):17-20.
[8] 李绍华,黄鸿辉,张永佳.强化阿托伐他汀治疗对急性心肌梗死患者急诊 PCI 术后 Lp-PLA2、IL-6 及心功能的影响[J].锦州医科大学学报,2018,39(2)64-66.
[9] Trine Moholdt,Carl J.Lavie,Javaid Nauman.Interaction of Physical Activity and Body Mass Index on Mortality in Coronary Heart Disease:Data from The Nord-Trndelag Health Study[J].Am J Med.2017 ,130(8):949-957.
[10] 贺卫国.培哚普利治疗冠心病患者心肌缺血的疗效[J].中国实用医刊,2011,38(20):62-64.
[11] 李翔宇,黄进,戴剑.培哚普利联合阿托伐他汀对高血压合并阵发性房颤患者炎症因子的干预作用[J].江苏医药,2016,42(24):2720-2722.
[12] 冷沁.氨氯地平并阿托伐他汀钙片改善高血压合并冠心病患者血脂和血压的效果[J].心血管康复医学杂志,2017,26(6):627-631.
[13] 王玉红,刘晖,冼志莲.阿托伐他汀联合阿司匹林对急性脑梗死患者血小板活化及炎性反应的影响[J].数理医药学杂志,2018,31(1):64-66.
[14] 陈伟,张亚西.硝苯地平控释片联合阿托伐他汀治疗高血压合并冠心病及对超敏C反应蛋白及血管内皮功能的影响[J].检验医学与临床,2015(1):40-42.
[15] 李广运.培哚普利联合瑞舒伐他汀治疗冠心病的疗效及对血管内皮功能与血小板活化功能的影响[J].中西医结合心脑血管病杂志,2018,16(1):70-73.
[16] 卓建明,林建武,钱文光,等.阿托伐他汀对急性脑梗死患者血浆炎症因子和血小板膜糖蛋白的影响[J].海峡药学,2010,22(3):101-102.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |